Research and original publication material
Takeda Pharmaceutical Company Limited Received a Patent for IC Compound — research background
Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.
Takeda is a research-based global pharmaceutical company. It is the largest pharmaceutical company in Japan, and one of the global leaders in the industry. Setting our management philosophy, "Takeda-ism" as the basis of business, Takeda is committed to striving towards better health for individuals and progress in medicine by developing superior pharmaceutical products.
Takeda Pharmaceutical Company Limited filed patent application numbered 1413/DELNP/2013 that is titled IC COMPOUND AND USE THEREOF. This patent application has been granted as Patent Number 311751.
The invention covers chemical compounds. This invention provides a compound represented by the formula (I):
wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer’s disease or attention deficit hyperactivity disorder (ADHD) and the like.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the claims 1-23 .These claims fall within the scope of Section 3(d) of the Indian Patent Act.
As a response to said objection, the applicant responded by submitting the legal arguments and requirement of the law has been picked up to prove the point.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
Discuss a research question related to Takeda Pharmaceutical Company Limited Received a Patent
Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.
Discuss a research questionSource and context: Original GIPResearch.com publication dated 2019-08-29. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

How to patent fintech inventions
Gen AI Innovations
What is Extended Reality
How to patent artificial intelligence based innovations
Patent claim drafting